Nurix Therapeutics (NRIX) CLO sells 8,148 shares in planned trade

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale of 8,148 shares of common stock at a weighted average price of $16.9624 per share. The transaction was executed pursuant to a previously adopted Rule 10b5-1 trading plan. Following this sale, she holds 18,305 shares directly.

Insights

Equity compensation and insider-trading analyst

Planned, open-market sale by Nurix’s CLO under a Rule 10b5-1 plan.

Nurix Therapeutics’ Chief Legal Officer, Christine Ring, sold 8,148 shares of common stock at a weighted average price of $16.9624 per share. This was an open-market sale, classified as code S, which is an active disposition.

The filing notes the sale occurred under a previously adopted Rule 10b5-1 trading plan, indicating the trades were pre-scheduled rather than opportunistic. After this transaction, Ring directly holds 18,305 shares, so she continues to maintain an equity stake while realizing some liquidity.

Insider Trade Summary 10b5-1

Net Seller: 8,148 shares ($138,210)

Net Sell 1 txn

Insider Ring Christine

Role Chief Legal Officer

Sold 8,148 shs ($138K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,148	$16.9624	$138K

Holdings After Transaction: Common Stock — 18,305 shares (Direct, null)

Footnotes (1)

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $16.78 and the highest price at which shares were sold was $17.26. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Key Figures

Shares sold: 8,148 shares Weighted average sale price: $16.9624 per share Price range of sales: $16.78–$17.26 per share +2 more

5 metrics

Shares sold 8,148 shares Open-market sale on May 4, 2026

Weighted average sale price $16.9624 per share Common stock sale on May 4, 2026

Price range of sales $16.78–$17.26 per share Range of execution prices for reported trades

Shares held after sale 18,305 shares Direct ownership following Form 4 transaction

Net shares sold 8,148 shares Net change in common stock position from this filing

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price. The lowest price at which shares were sold was $16.78 and the highest price was $17.26."

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		S(1)		8,148	D	$16.9624(2)	18,305	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $16.78 and the highest price at which shares were sold was $17.26. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Nurix Therapeutics (NRIX) disclose in Christine Ring’s latest Form 4?

Nurix Therapeutics reported that Chief Legal Officer Christine Ring sold 8,148 shares of common stock in an open-market transaction at a weighted average price of $16.9624 per share, and now directly holds 18,305 shares after the sale.

How many Nurix Therapeutics (NRIX) shares did the CLO sell and at what price?

Christine Ring sold 8,148 shares of Nurix Therapeutics common stock at a weighted average price of $16.9624 per share. The filing notes a price range from $16.78 to $17.26, reflecting multiple sales within that band.

Was the Nurix Therapeutics (NRIX) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transaction was effected under a previously adopted Rule 10b5-1 trading plan. Such plans pre-schedule trades, indicating the timing of this 8,148-share sale was pre-arranged rather than a discretionary market-timing decision.

How many Nurix Therapeutics (NRIX) shares does Christine Ring hold after this Form 4 transaction?

After selling 8,148 shares, Chief Legal Officer Christine Ring directly holds 18,305 shares of Nurix Therapeutics common stock. This remaining position shows she continues to have direct equity exposure to the company following the reported open-market sale.

What price range is disclosed for the Nurix Therapeutics (NRIX) insider stock sales?

The Form 4 reports a weighted average sale price of $16.9624 per share. It also specifies that individual trades occurred between a low of $16.78 and a high of $17.26, reflecting multiple executions within that range.